Experience

Kayentis

• France
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Business Unit Manager

  • Jun 2022 - Present

• Manager, Clinical Operations Project Management team

  • Apr 2021 - May 2022

• Clinical Operations Project Manager

  • Dec 2019 - Mar 2021



PHAXIAM Therapeutics

• France
• Biotechnology
• 1 - 100 Employee

• R&D Project Manager

  • Jan 2019 - Nov 2019

• R&D Associate Research Scientist

  • Mar 2018 - Dec 2018

• Research Engineer in Immunotherapy

  • Feb 2017 - Mar 2018

• Research Assistant in Immunotherapy

  • May 2016 - Jan 2017



PDC*line Pharma

• Belgium
• Biotechnology Research
• 1 - 100 Employee

• Research Engineer in Immuno-oncology (Ingénieur d'études)

  • Nov 2015 - Dec 2015

  Two month contract working on the mechanism of action and the optimization of a therapeutic dendritic cell-based cancer vaccine. Missions included characterization of a dendritic cell line and T cells by flow cytometry and cytokine dosage by ELISA and CBA. Two month contract working on the mechanism of action and the optimization of a therapeutic dendritic cell-based cancer vaccine. Missions included characterization of a dendritic cell line and T cells by flow cytometry and cytokine dosage by ELISA and CBA.



EFS

• France
• Government Administration
• 700 & Above Employee

• Research Engineer in training

  • Jan 2015 - Jul 2015

  "Mechanism of Action of GENiusVac-Mel4: A Dendritic Cell-Based Therapeutic Melanoma Vaccine." Six months elucidating the mechanism of action and validating the proof of concept of GENiusVac, a dendritic cell-based vaccine to treat melanoma, currently in a phase Ib clinical trial. Missions included creating and putting into place antibody panels for T cell characterization and finding key cells and cytokines involved in the dendritic cell-T cell interaction. "Mechanism of Action of GENiusVac-Mel4: A Dendritic Cell-Based Therapeutic Melanoma Vaccine." Six months elucidating the mechanism of action and validating the proof of concept of GENiusVac, a dendritic cell-based vaccine to treat melanoma, currently in a phase Ib clinical trial. Missions included creating and putting into place antibody panels for T cell characterization and finding key cells and cytokines involved in the dendritic cell-T cell interaction.



INSERM

• France
• Research Services
• 700 & Above Employee

• Research Engineer in training

  • Apr 2014 - May 2014

  "Development of new cell lines for cell-based therapy to prevent glioblastoma recurrence after radiotherapy." Tasks included viral vector construction, viral transduction to create transgenic cell lines, and culture of mammalian and bacterial cells. "Development of new cell lines for cell-based therapy to prevent glioblastoma recurrence after radiotherapy." Tasks included viral vector construction, viral transduction to create transgenic cell lines, and culture of mammalian and bacterial cells.



University of Joseph Fourier, Grenoble

• Higher Education
• 1 - 100 Employee

• Intern

  • Jan 2014 - Feb 2014

  Two practical labs lasting two weeks each. For the cell engineering lab, responsibilities included creating and using protocols for the optimization of hybridoma culture and monoclonal antibody production, purification, and analysis. For the protein engineering lab, tasks included the production, purification, and biochemical analysis of a recombinant protein with directed mutagenesis. Two practical labs lasting two weeks each. For the cell engineering lab, responsibilities included creating and using protocols for the optimization of hybridoma culture and monoclonal antibody production, purification, and analysis. For the protein engineering lab, tasks included the production, purification, and biochemical analysis of a recombinant protein with directed mutagenesis.